Chidozie Ugwumba Sells 5,736 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 5,736 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $6.08, for a total value of $34,874.88. Following the completion of the sale, the insider owned 277,569 shares in the company, valued at $1,687,619.52. This trade represents a 2.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, April 29th, Chidozie Ugwumba sold 12,170 shares of Clene stock. The stock was sold at an average price of $5.63, for a total value of $68,517.10.
• On Tuesday, April 28th, Chidozie Ugwumba sold 1,591 shares of Clene stock. The stock was sold at an average price of $5.90, for a total value of $9,386.90.
• On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The stock was sold at an average price of $6.14, for a total value of $376,658.30.
• On Monday, April 20th, Chidozie Ugwumba sold 4,318 shares of Clene stock. The stock was sold at an average price of $6.12, for a total value of $26,426.16.
• On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total value of $161,007.20.
• On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total value of $49,587.20.
• On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total value of $41,303.52.
• On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The shares were sold at an average price of $4.81, for a total value of $119,889.25.
• On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The shares were sold at an average price of $4.97, for a total value of $21,261.66.
• On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The shares were sold at an average price of $4.10, for a total value of $22,791.90.

Clene Stock Down 0.3%

CLNN opened at $6.14 on Friday. The stock has a market cap of $72.33 million, a PE ratio of -2.36 and a beta of 0.89. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The business’s fifty day simple moving average is $5.68 and its 200 day simple moving average is $6.50.

Clene (NASDAQ:CLNN) last released its earnings results on Thursday, March 12th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. As a group, equities analysts anticipate that Clene Inc. will post -1.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CLNN. Jane Street Group LLC bought a new position in shares of Clene during the second quarter valued at about $47,000. Scoggin Management LP grew its stake in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Clene during the third quarter valued at about $29,000. Lunt Capital Management Inc. grew its stake in shares of Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after buying an additional 1,250 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Clene by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after buying an additional 6,090 shares during the last quarter. 23.28% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CLNN. Weiss Ratings cut Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a research note on Friday, March 13th. Finally, D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of Clene in a research note on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).